Organization
Federal Circuit ruling allows Amgen’s Eylea biosimilar to stay on the market
Market, Amgen ‘s, Pavblu, Amgen, Eylea biosimilar, Regeneron, Federal Circuit, court, Eylea
Roche expands obesity pipeline, paying Zealand Pharma $1.65B upfront to codevelop amylin asset
This deal represents a major expansion of Roche’s obesity drug pipeline and a significant partnership in the competitive weight loss medication market.
Daiichi turns to Nosis for AI-designed RNA delivery tech
Nosis, Daiichi, RNA, Sankyo, Partnership, Biosciences, Cells, Chronic disease
BMS snaps up Abecma partner 2seventy bio in $286M all-cash deal
Burning Mouth Syndrome, Abecma, BMS, Abecma
US judge blocks Trump administration from cutting NIH grants amid ongoing litigation
United States National Institutes of Health, Judge, injunction, implementing
FDA puts BioNTechs malaria vaccine on clinical hold
United States Food and Drug Administration, Malaria, Study on Hold, Vaccines, BioNTech ‘s, Clinical Trials
DOGE terminates leases for 30 FDA sites across 23 states
DOGE, United States Food and Drug Administration, Site, United States Food and Drug Administration, Clinical action, Government, leases
Merck & Co. predicts Keytruda will undergo IRA price cuts before patent cliff
Merck, Keytruda, Prices, IRA, Sales – occupational activity, patent cliff, Impact food supplement, U.S., Keytruda
Hims eyes growth in its weight loss business, despite end of semaglutide shortage
semaglutide, weight loss business, United States Food and Drug Administration, Growth, Hims